Gilead to Acquire Tubulis GmbH for $5 Billion

Gilead announced its intention to acquire the German biotechnology company Tubulis GmbH for up to $5 billion. This strategic acquisition aims to significantly enhance Gilead's pipeline of experimental cancer drugs, specifically those classified as "guided missiles." The deal underscores Gilead's commitment to expanding its oncology portfolio with innovative therapies. The acquisition is expected to bolster the company's position in the competitive cancer drug market by integrating Tubulis's promising technology.